BeStock  
Stocks › IOVA

Iovance Biotherapeutics IOVA

US equityMarket cap rank #2386
$6.90 −$0.41 (-5.61%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $6.99 +1.25%
Open$7.17
Prev close$7.31
Day range$6.77 – $7.40
Volume13.73M
Market cap$3.19B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$121.47M+80.1% YoY
Operating profit-$23.97M+73.3% YoY
Net profit-$22.27M+75.6% YoY
Diluted EPS-$0.05+80.0% YoY
Free cash flow-$9.31M+89.6% YoY
Operating cash flow-$4.47M

Revenue, last 8 quarters

$73.7MDec '24$49.3MMar '25$60.0MJun '25$67.5MSep '25$86.8MDec '25$71.4MMar '26$99.3MJun '26$121.5MSep '26

Net profit, last 8 quarters

$-78.6MDec '24$-116.2MMar '25$-111.7MJun '25$-91.3MSep '25$-71.9MDec '25$-79.0MMar '26$-47.3MJun '26$-22.3MSep '26

Diluted EPS by quarter

-0.26Dec '24-0.36Mar '25-0.33Jun '25-0.25Sep '25-0.18Dec '25-0.19Mar '26-0.11Jun '26-0.05Sep '26

Free cash flow by quarter

$-77.5MDec '24$-109.9MMar '25$-74.9MJun '25$-89.5MSep '25$-61.9MDec '25$-78.7MMar '26$-66.3MJun '26$-9.3MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$1.2MFY23$164.1MFY24$263.5MFY25

Profitability & balance sheet

Gross margin53.2%
Operating margin-60.8%
Net margin-58.2%
Return on equity-29.1%
Return on assets-23.3%
Return on invested capital-28.4%
Current ratio5.20
Liabilities / assets18.0%
Cash & investments$376.32M
Total debt$42.77M
Net cash (debt)$333.55M

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Amtagvi$101.60M 83.6%
  • Proleukin$19.87M 16.4%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $121.47M $99.31M $71.43M $263.50M $86.77M
Total Operating Revenue $121.47M $99.31M $71.43M $263.50M $86.77M
Cost of Revenue $48.03M $43.60M $42.50M $173.18M $43.11M
Gross Profit $73.44M $55.72M $28.93M $90.32M $43.66M
Operating Expense $97.41M $107.62M $109.98M $488.53M $117.12M
Selling and Admin Expenses $38.58M $39.27M $38.95M $152.32M $36.40M
Research & Development $49.34M $58.85M $62.49M $300.27M $71.20M
Depreciation & Amortization & Depletion $9.50M $9.50M $8.54M $35.94M $9.52M
-Depreciation & Amortization $9.50M $9.50M $8.54M $35.94M $9.52M
Operating Profit -$23.97M -$51.91M -$81.04M -$398.21M -$73.46M
Net Non-Operating Interest Income (Expense) $2.31M $3.22M $1.33M $10.31M $1.74M
Non-Operating Interest Income $2.31M $3.22M $1.33M $10.31M $1.74M
Special Income (Charges) $0.00 – – -$5.14M $0.00
-Less:Restructuring and Mergern & Acquisition $0.00 – – $5.14M $0.00
Pretax Profit -$21.66M -$48.69M -$79.71M -$393.05M -$71.72M
Tax $614,000.00 -$1.37M -$665,000.00 -$2.07M $184,000.00
Net Profit -$22.27M -$47.32M -$79.05M -$390.98M -$71.90M
Profit from Continuing Operations -$22.27M -$47.32M -$79.05M -$390.98M -$71.90M
Net Income to Parent Company -$22.27M -$47.32M -$79.05M -$390.98M -$71.90M
Net Income to Common Stockholders -$22.27M -$47.32M -$79.05M -$390.98M -$71.90M
Basic EPS -$0.05 -$0.11 -$0.19 -$1.09 -$0.18
Diluted EPS -$0.05 -$0.11 -$0.19 -$1.09 -$0.18
Other Income (Expense) – – – -$5.14M $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $991.21M $915.53M $925.67M $913.17M $913.17M
Total Current Assets $549.64M $464.26M $466.50M $442.69M $442.69M
Cash and Cash Equivalents & Short-Term Investments $376.32M $110.77M $313.44M $296.98M $296.98M
-Cash and Cash Equivalents $57.93M $110.77M $196.51M $163.08M $163.08M
-Short Term Investments $318.39M – $116.94M $133.90M $133.90M
Receivables $106.99M – $81.76M $82.45M $82.45M
-Accounts Receivable $106.99M $102.12M $81.76M $82.45M $82.45M
Inventory $55.22M $55.59M $58.38M $51.68M $51.68M
Other Current Assets $11.11M $408.67M $12.93M $11.58M $11.58M
Total Non-Current Assets $441.58M $451.27M $459.16M $470.48M $470.48M
Net PPE $171.87M – $175.78M $177.01M $177.01M
-Gross PPE $231.99M – $228.15M $225.78M $225.78M
-Accumulated Depreciation -$60.12M – -$52.37M -$48.77M -$48.77M
Goodwill and Other Intangible Assets $259.21M $263.89M $269.10M $279.32M $279.32M
-Other Intangible Assets $259.21M $263.89M $269.10M – –
Other Non-Current Assets $10.50M $187.38M $14.28M $14.15M $14.15M
Total Liabilities $178.55M $179.49M $203.91M $214.59M $214.59M
Total Current Liabilities $105.77M $106.85M $129.42M $138.36M $138.36M
Payables $21.65M – $37.45M $22.16M $22.16M
-Accounts Payable $21.65M $26.21M $37.45M $22.16M $22.16M
Current Accrued Expenses $81.69M $77.96M $88.07M $111.16M $111.16M
Short-Term Debt and Capital Lease Obligation $2.44M – $3.90M $5.04M $5.04M
-Current Capital Lease Obligation $2.44M $2.67M $2.90M $4.04M $4.04M
Total Non-Current Liabilities $72.78M $72.64M $74.49M $76.23M $76.23M
Long Term Debt and Capital Lease Obligation $42.77M $43.33M $43.88M $44.40M $44.40M
-Long Term Capital Lease Obligation $42.77M $43.33M $43.88M $44.40M $44.40M
Non-Current Deferred Liabilities $30.01M – $30.61M $31.83M $31.83M
Total Equity $812.66M $736.05M $721.75M $698.58M $698.58M
Stockholders' Equity $812.66M $722.95M $721.75M $698.58M $698.58M
Capital Stock $21,000.00 $2,000.00 $20,000.00 $19,000.00 $19,000.00
-Common Stock $19,000.00 – $18,000.00 $17,000.00 $17,000.00
-Preferred Stock $2,000.00 $2,000.00 $2,000.00 $2,000.00 $2,000.00
Additional Paid-In Capital $3.72B $3.62B $3.56B $3.46B $3.46B
Retained Earnings -$2.92B -$2.90B -$2.85B -$2.78B -$2.78B
Gains/Losses Not Affecting Retained Earnings $13.85M – $12.65M $16.44M $16.44M
-Current Debt – – $1.00M $1.00M $1.00M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$4.47M -$60.84M -$72.07M -$302.41M -$52.57M
Net cash flow from continuing operations -$4.47M -$60.84M -$72.07M -$302.41M -$52.57M
Net Income from Continuing Operations -$22.27M -$47.32M -$79.05M -$390.98M -$71.90M
Gain/Loss from Continuing Operations $62,000.00 -$355,000.00 $462,000.00 -$194,000.00 -$373,000.00
Depreciation & Depletion & Amortization $10.42M $10.40M $10.42M $47.32M $12.64M
Deferred Tax $614,000.00 -$1.37M -$665,000.00 -$2.07M $184,000.00
Change in Working Capital -$3.34M -$35.83M -$12.88M -$24.27M -$7.29M
-Change in Receivables -$4.87M -$20.36M $690,000.00 -$13.11M -$15.69M
-Change in Inventory $596,000.00 -$177,000.00 -$4.93M -$14.21M -$4.00M
-Change in Prepaid Assets -$282,000.00 $5.91M -$1.47M -$8.02M -$661,000.00
-Change in Payables and Accrued Expense $2.01M -$20.43M -$5.15M $21.98M $15.96M
-Change in Other Current Liabilities -$792,000.00 -$773,000.00 -$2.03M -$10.90M -$2.90M
Net cash flow from investing -$134.65M -$74.05M $11.39M $47.50M $775,000.00
Net Cash Flow from Continuing Investing Activities -$134.65M -$74.05M $11.39M $47.50M $775,000.00
Net PPE Purchase and Sale -$4.74M -$5.44M -$6.61M -$33.84M -$9.32M
Net Investment Purchase and Sale -$129.81M -$68.61M $18.00M $81.33M $10.10M
Financing Cash Flow $86.28M $49.29M $94.34M $300.77M $56.17M
Net Cash Flow from Continuing Financing Activities $86.28M $49.29M $94.34M $300.77M $56.17M
Net Common Stock Issuance $87.90M $49.57M $98.51M $306.31M $55.78M
Proceeds from Stock Option Exercised $805,000.00 $887,000.00 $0.00 $1.53M $839,000.00
Net Other Financing Charges -$2.42M -$1.17M -$4.18M -$7.06M -$445,000.00
Ending Cash Balance $63.95M $116.77M $202.50M $169.06M $169.06M
Net Change in Cash -$52.83M -$85.60M $33.66M $45.86M $4.38M
Beginning Cash Balance $116.77M $202.50M $169.06M $122.05M $164.10M
Effect of Exchange Rate Changes $11,000.00 -$124,000.00 -$213,000.00 $1.14M $577,000.00
Free Cash Flow -$9.31M -$66.28M -$78.68M -$336.24M -$61.89M
Net Business Purchase and Sale – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on IOVA.

Sign in to join the discussion.

Scroll to Top